HSC frequency and function using different flow criteria
| HSC measure . | Young AL . | Old AL . | Old DR . |
|---|---|---|---|
| mKSL criterion | |||
| LT-HSC/106 viable BMC | 99 ± 19 | 1847 ± 341* | 752 ± 145* |
| RU/106 viable BMC | 10 ± 2 | 6 ± 3 | 15 ± 4 |
| RU/103 LT-HSC | 107 ± 29 | 2 ± 1† | 21 ± 2‡ |
| SP+Kit criterion | |||
| HSC/106 viable BMC | 261 ± 48 | 199 ± 68 | 336 ± 56 |
| RU/106 viable BMC | 11 ± 3 | 0.3 ± 0.1† | 17 ± 7 |
| RU/103 HSC | 47 ± 21 | 2 ± 1† | 54 ± 26 |
| HSC measure . | Young AL . | Old AL . | Old DR . |
|---|---|---|---|
| mKSL criterion | |||
| LT-HSC/106 viable BMC | 99 ± 19 | 1847 ± 341* | 752 ± 145* |
| RU/106 viable BMC | 10 ± 2 | 6 ± 3 | 15 ± 4 |
| RU/103 LT-HSC | 107 ± 29 | 2 ± 1† | 21 ± 2‡ |
| SP+Kit criterion | |||
| HSC/106 viable BMC | 261 ± 48 | 199 ± 68 | 336 ± 56 |
| RU/106 viable BMC | 11 ± 3 | 0.3 ± 0.1† | 17 ± 7 |
| RU/103 HSC | 47 ± 21 | 2 ± 1† | 54 ± 26 |
For each flow criterion, the frequency (± SE) of HSCs and functional abilities (RU) were determined in separate groups of BALB BMC donors that are subsets of those presented in Figure 2A,B. The mKSL flow criterion48 used lineage−, Sca-1+, c-Kit+, CD34−, and Flk2−, whereas the SP+Kit criterion used the Hoescht effluxing, double-negative side population,37,38,44,45 plus c-Kit+. Because HSCs were defined per viable BMC and functional ability (RU) per total BMCs, the ratio is a lower limit. However, flow cytometry viabilities were about the same in both experiments, so relative ratios are correct.
P < .001 versus young AL controls.
P < .01 versus young AL controls.
P < .05 versus young AL controls.